Drug intelligence / Profile preview

epoetin beta

Development stage
Approved
Lead developer
Roche
Modality
Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration
Intravenous, Subcutaneous
01

Overview

Epoetin beta is a synthetic, recombinant form of human erythropoietin, a glycoprotein hormone that stimulates the production of red blood cells by acting on erythroid progenitor cells in the bone marrow. It is produced using Chinese hamster ovary (CHO) cells and has an identical amino acid sequence to endogenous human erythropoietin. Epoetin beta is classified as an erythropoiesis-stimulating agent (ESA) and is primarily used to treat anemia associated with chronic kidney failure and cancer chemotherapy. It increases red blood cell production by binding to the erythropoietin receptor on target cells, thereby promoting differentiation and proliferation of these precursors into mature red blood cells[5].

Brand names
Neorecormon
Other names
recombinant human erythropoietin betarHuEPO-beta
02

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on epoetin beta.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on epoetin beta.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call